Educational guide
ACL injury management: a comprehensive review of novel ...
5 Biological treatments 5.1 Hyaluronic acid (HA) and other scaffolds therapy Hyaluronic acid (HA), a linear polysaccharide, is ubiquitously present within the extracellular matrix and synovial fluid of various connective tissues. HA exerts a significant influe
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
5 Biological treatments
5.1 Hyaluronic acid (HA) and other scaffolds therapy
Hyaluronic acid (HA), a linear polysaccharide, is ubiquitously present within the extracellular matrix and synovial fluid of various connective tissues. HA exerts a significant influence on cellular processes, including proliferation and differentiation, through its modulation of cell-matrix interactions (Skandalis et al., 2020; Iaconisi et al., 2023; Knapik et al., 2021). These regulatory mechanisms underscore the pivotal role of HA in the realms of tissue repair and cellular biology. By facilitating dynamic interactions between cells and their surrounding matrix, HA contributes to the orchestration of cellular behaviors that are integral to the maintenance of tissue homeostasis and the restoration of tissue integrity following injury (Marinho et al., 2021; ).
5.1.1 HA and animal models
Investigations into the therapeutic application of HA for the treatment of ACL injuries are predominantly in the preclinical phase. Dating back to 1990, a seminal study demonstrated that the administration of HA injections could foster ligamentous healing by augmenting angiogenesis and mitigating inflammatory responses during the early reparative phase of partial-ACL tears in a rabbit model (Wiig et al., 1990). Subsequent research by Yoneda et al. indicated that the intra-articular injection of high molecular weight HA into injured ACLs of rabbits not only enhanced collagen remodeling but also stimulated an increase in fibroblast activity, indicative of a heightened collagen synthesis. Concurrently, HA treatment led to a significant attenuation of inflammatory responses and a proliferation of fibroblasts within the regions of tissue repair. However, it is noteworthy that despite 12 weeks of treatment with high molecular weight HA, a non-healing rate of 33.33% was observed (Wiig et al., 1990). Furthermore, HA degradation products, specifically disaccharide fragments ranging from 4 to 25 units in length, have been shown to promote angiogenesis and provide a structural framework conducive to ACL repair (Yoneda et al., 1988a; Yoneda et al., 1988b). Collectively, these findings suggest that while HA holds promise as a therapeutic agent for ACL injury, further research and refinement of HA-based treatment modalities are imperative to optimize their clinical efficacy and safety. In a study of the effects of intra-articular injection of hyaluronic acid (HA) on the biomechanical properties and histological changes of the anterior cruciate ligament (ACL) in rats, the results showed that intra-articular injection of HA did not significantly affect the tensile strength of the ACL in rats, and no significant effects were observed on other markers of degenerative change (Yucel et al., 2009). In Balasubramaniyan’s study, researchers engineered an ultra-high molecular weight polyethylene (UHMWPE) braided structure for anterior cruciate ligament (ACL) reconstruction, enhancing its biocompatibility through innovative surface modifications. The UHMWPE was treated with low-temperature plasma and subsequently coated with cationized gelatin and hyaluronic acid, creating a construct that not only upheld the integrity of the ligament but also fostered a favorable environment for integration with native tissues. The in-vitro cytotoxicity and genotoxicity assays confirmed the non-toxic and non-mutagenic nature of the ACL extract, while in-vivo analyses revealed that the treated ligament was non-irritating, non-sensitizing, and actively promoted the formation of new tissue around the graft ().
5.1.2 HA and human ACL repair
In the evolutionary journey of tissue engineering, the year 2008 marked a significant milestone with the introduction of HA into human clinical trials, specifically for the purpose of reconstructing engineered ligament tissue. Pioneering work by Young-Kwon and colleagues led to the development of an innovative composite scaffolding system. This system integrated fiber materials within an HA matrix and was successfully transplanted in vivo, demonstrating not only excellent biocompatibility but also significant promotion of neovascularization and cell migration, as evidenced by Seo et al. (2009), Kwon et al. (2013). These findings have laid a critical theoretical and empirical groundwork for the use of HA as a pivotal component in the construction of tissue-engineered ligaments, particularly for the repair of damaged ACL. ACL and meniscus injuries, prevalent among athletes and the general population, can lead to early post-traumatic osteoarthritis in 50–60 percent of patients, regardless of whether reconstructive surgery is performed. The anti-inflammatory, anabolic, and chondroprotective effects of hyaluronic acid have been demonstrated in vitro and in animal models. Intra-articular injections of hyaluronic acid have proven beneficial in young patients with acute knee injuries, including symptomatic meniscal tears and isolated ACL injuries with cartilage damage. As noted by Jazrawi and Rosen (2011), intra-articular injections of hyaluronic acid are efficacious for non-traumatic osteoarthritis and are endorsed by current treatment guidelines (Jazrawi and Rosen, 2011). The seamless integration of HA into scaffold design for ligament tissue engineering signifies a notable advancement in the field, presenting a promising pathway for the development of more efficacious ACL repair strategies. A study conducted by Hu et al. (2023) aimed to evaluate the therapeutic benefits of combining arthroscopic anterior cruciate ligament reconstruction (AACLR) with sodium hyaluronate (SH) in ACL injury patients, both with and without early knee osteoarthritis (KOA). The inflammatory response was meticulously monitored using enzyme-linked immunosorbent assay (ELISA) for serum inflammatory markers. Knee functionality was comprehensively assessed using the lysholm knee score, the international knee documentation committee (IKDC) knee evaluation form, and by measuring the range of motion of the knee joint. The study concluded that AACLR combined with SH effectively improves knee function and reduces inflammation in ACLI patients, irrespective of their KOA status (Hu et al., 2023). Despite the progress of tissue engineering, which has given rise to numerous bioengineering techniques for the repair of ACL injuries, the majority of these techniques remain in the preclinical animal experiment stage. Translation to widespread clinical practice has been gradual, underlining the need for further research and development to harness the full potential of these advancements in orthopedic medicine.
5.1.3 Other scaffolding materials
5.1.3.1 Aligned gelatin microribbon scaffolds with hydroxyapatite gradientThis study introduces a pioneering strategy in the realm of tissue engineering, specifically tailored to surmount the reparative challenges encountered at the bone-tendon interface. The investigators have crafted an innovative aligned gelatin microribbon (μRB) hydrogel scaffold, replete with a meticulously designed gradient of hydroxyapatite nanoparticles (HA-np). This construct is meticulously engineered to orchestrate the zonal-specific differentiation of human mesenchymal stem cells (hMSCs), effectively emulating the intricate natural gradient of the bone-tendon interface. The aligned μRBs within the scaffold serve as a structural guide, promoting cell alignment in three-dimensional space. Moreover, the HA-np gradient is instrumental in driving the mesenchymal stem cells towards a differentiation pathway that closely mirrors the native tissues at the bone-tendon junction. The introduction of a brief chondrogenic priming phase, preceding exposure to osteogenic factors, refines this mimicry of the bone-cartilage-tendon transition, substantially augmenting the tensile modulus of the resulting engineered tissues. Divergent from prior methodologies, which often necessitated the use of composite materials and multilayer scaffolding techniques, this research presents a paradigm shift with a continuous scaffold system that capitalizes on a single cell source. The 3D macroporous microribbon hydrogel platform, featuring aligned structural cues in conjunction with the zonal integration of hydroxyapatite nanoparticles, facilitates seamless differentiation across the bone-tendon interface. This unified approach not only streamlines the tissue engineering process but also holds great promise for enhancing the functional and mechanical properties of the engineered interface, thereby advancing the field of regenerative medicine (Stanton et al., 2022).
5.1.3.2 Bioactive strontium substituted hydroxyapatite for polyethylene terephthalate artificial ligamentsIn this thorough investigation, the capacity of strontium-substituted hydroxyapatite (SrHA) nanoparticles to augment the bioactivity and osseointegration of polyethylene terephthalate (PET) artificial ligaments, extensively applied in ACL reconstruction surgeries, has been rigorously evaluated. The prevalent use of PET ligaments, while beneficial, is often compromised by the challenge of suboptimal healing at the ligament-bone interface. Through an innovative microwave-hydrothermal synthesis, SrHA nanoparticles with varying strontium content were developed and applied as a coating to PET ligaments, significantly modulating their chemical composition and crystallinity without disrupting the phase or morphology. The application of these nanoparticles was confirmed through scanning electron microscopy (SEM), which provided visual evidence of their successful and uniform deposition onto the PET ligament surfaces, concurrent with a marked enhancement in surface hydrophilicity due to the coatings. This surface modification is anticipated to improve the interaction with biological systems and promote osseointegration. In vitro studies illuminated the impact of Sr ion concentrations on the osteogenic potential of rat bone marrow mesenchymal stem cells (rBMSCs), with the 2SrHA-PET group evidencing the most favorable osteogenic differentiation. This was underscored by the upregulation of key osteogenic genes BMP-2, OCN, Col-I, and VEGF, which are integral to bone formation and repair processes. The in vivo studies corroborated these promising in vitro results, demonstrating that the 2SrHA-PET group possessed an enhanced osteogenic capacity, leading to superior ligament-bone integration and increased biomechanical strength when compared to groups treated with PET and HA-PET. The research culminates in the compelling conclusion that SrHA nanoparticle coatings offer a promising strategy to bolster osseointegration in ligament repair. This innovative application presents a transformative modification method for PET artificial ligaments in ACL reconstruction, leveraging Sr-containing biomaterials to substantially ameliorate ligament-bone healing. This advancement is poised to enhance clinical outcomes for patients undergoing ACL reconstructive procedures, offering a significant stride forward in the domain of orthopedic sports medicine (Stanton et al., 2022).
5.1.3.3 Bone-ligament-bone integrated scaffoldThe study presents the innovative design and development of a multiphasic bone-ligament-bone (BLB) integrated scaffold, specifically engineered for ACL reconstruction. This advanced scaffold is composed of polylactic acid (PLA) and deferoxamine (DFO) encapsulated within mesoporous hydroxyapatite (MHA) through a thermally induced phase separation (TIPS) process, complemented by silk fibroin (SF) and connective tissue growth factor (CTGF) embedded within Poly (L-lactide-co-ε-caprolactone) (PLCL) nanofiber yarns, crafted into a braided configuration. The mechanical properties of the BLB scaffold were meticulously assessed and confirmed to align with those of human ACLs, indicating its potential for effective clinical use. In vitro studies demonstrated that CTGF successfully stimulated the expression of genes vital for ligament formation, while the TIPS scaffolds, enriched with MHA and DFO, significantly enhanced osteogenic gene expression within bone marrow stem cells (BMSCs). These scaffolds also fostered the migration and tubular formation of human umbilical vein endothelial cells (HUVECs), indicating a promising capacity to support vascularization.
Within a rabbit model, the BLB scaffold proved instrumental in promoting ligamentization and graft-bone integration, effectively delivering bioactive substances to the repair site. The synergistic effect of dual delivery of DFO and calcium ions by the BLB scaffold was particularly noteworthy, as it significantly advanced bone regeneration. Concurrently, CTGF contributed to enhanced collagen formation and accelerated ligament healing, underscoring the scaffold’s multifaceted approach to ACL reconstruction and its potential to set a new benchmark in orthopedic biomaterials (Xie et al., 2024).
5.1.3.4 Polycaprolactone/hydroxyapatite/collagen-based fiber scaffoldThis study endeavored to ascertain the characteristics of an anterior cruciate ligament (ACL) scaffold composed of polycaprolactone (PCL), hydroxyapatite (HA), and collagen, across a spectrum of weight ratios: (50:45:5), (50:40:10), (50:35:15), (50:30:20), and (50:25:25). All specimens exhibited an average fiber diameter beneath the 1,000 nm threshold, signifying a nanoscale structure. Prominently, the scaffold with a 50:45:5 PCL:HA:collagen ratio demonstrated the most favorable attributes, including an average fiber diameter of 488 ± 271 nm. In terms of mechanical performance, the braided samples showcased an ultimate tensile strength (UTS) of 2.796 MPa and a modulus of elasticity of 3.224 MPa. In contrast, the non-braided counterparts possessed a UTS of 2.864 MPa and a notably higher modulus of elasticity at 12.942 MPa. The scaffolds were projected to degrade over an estimated period of 9.44 months. Furthermore, cytotoxicity evaluations confirmed the non-toxic nature of the samples, with a robust cell viability rate of 87.95%. These findings underscore the potential of the optimized 50:45:5 PCL:HA:collagen scaffold as a viable candidate for ACL regeneration applications ().
5.1.4 HA treatment limitations
While HA therapy presents a promising avenue for enhancing the healing of the ACL and restoring joint homeostasis, several limitations and challenges must be critically acknowledged and addressed to fully harness its therapeutic potential:
1) Limited Residence Time and Bioavailability: A primary challenge with HA treatment is its transient residence time in vivo, which may constrain its capacity to provide a prolonged therapeutic impact. To surmount this obstacle, researchers are investigating various strategies, including the administration of repeated injections, the development of slow-release formulations, and the use of HA-loaded stents, all aimed at prolonging HA’s duration of action and bolstering its regenerative capabilities (Ong et al., 2021).
2) Variable Molecular Weight and Composition: The efficacy of hyaluronic acid is contingent upon its molecular weight, the extent of its crosslinking, and the purity of the preparation. The standardization of HA products and the optimization of their physicochemical characteristics are paramount to ensuring reliable and uniform treatment outcomes (Mao et al., 2023).
3) Insufficient Clinical Efficacy Evidence: Despite the positive findings from preclinical studies on HA’s role in ACL healing, robust clinical evidence supporting its application in clinical practice is scarce. There is a need for well-designed, placebo-controlled, randomized clinical trials with substantial sample sizes and long-term follow-up periods to firmly establish the clinical efficacy of HA in the treatment of ACL injuries (Ong et al., 2021).
4) Potential Interactions with Other Therapies: In exploring HA as a potential therapy for ACL injuries, it is imperative to consider the local joint microenvironment, where HA can interact with other bioactive substances. These interactions may alter the therapeutic efficacy or safety of HA. Therefore, a comprehensive understanding of these potential interactions and the development of strategies to mitigate any adverse effects are crucial for safely and effectively integrating HA into a comprehensive, multimodal treatment plan. As previously mentioned, following ACL injury, the concentration of MMP-3 in the joint cavity fluid increases. MMPs are a group of enzymes that play a pivotal role in the degradation and remodeling of the ECM. The accumulation of intra-articular MMP-3 may hinder the healing process of the ACL, as they can degrade various ECM components, including HA (Wan et al., 2021). TNF-α is a significant pro-inflammatory cytokine that activates immune cells, such as macrophages and neutrophils. These cells release a variety of enzymes, including MMPs, during the inflammatory response, promoting the degradation of HA. Moreover, TNF-α may have synergistic effects with other inflammatory factors like IL-1β and IL-6, which could enhance the expression and activity of MMPs, further affecting the stability and functionality of HA (Xiao et al., 2021). To optimize the therapeutic potential of HA, the inflammatory joint microenvironment must be taken into account, and it may be necessary to modulate these inflammatory pathways through combination therapy or other interventions to protect HA from premature degradation, thereby supporting the recovery process of ACL injuries while minimizing potential adverse reactions.
5) Cost-Effectiveness and Accessibility: The financial implications of HA-based therapies, particularly when integrated with other advanced treatment modalities such as stents or serial injections, may present a barrier to their broad adoption. A thorough evaluation of the cost-effectiveness of hyaluronic acid therapy in comparison to traditional treatments, coupled with efforts to reduce expenses without sacrificing therapeutic efficacy, is vital for its consideration as a routine clinical intervention (Wan et al., 2021).
5.2 Stem cell therapy
5.2.1 Mesenchymal stem cells (MSCs)
In the contemporary biomedical landscape, mesenchymal stem cells (MSCs), characterized by their pluripotency, self-renewal capacity, and ability to differentiate into a spectrum of cell types, have emerged as a focal point of regenerative medicine. Their therapeutic potential has been extensively substantiated through rigorous evaluation in both animal models and human clinical studies. MSCs have been shown to exert salutary effects on angiogenesis, cell proliferation, and the modulation of inflammatory responses, in addition to the secretion of a myriad of bioactive molecules that are integral to tissue repair mechanisms (Marolt Presen et al., 2019; ).
Recent scholarly work has suggested that the therapeutic efficacy of MSCs in the treatment of ACL injuries may be predominantly facilitated through the release of exosomes (Lui, 2021; Zou et al., 2023). Mesenchymal stem cell-derived exosomes (MSC-exos) are extracellular vesicles of nanometer dimensions that serve as conduits for intercellular communication. These vesicles are capable of transporting a constellation of biologically active molecules, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiopoietin-1, monocyte chemotactic protein-1, interleukin-6 (IL-6), and placental growth factor, thereby exerting regulatory effects on the physiological and pathological processes within recipient cells (; Liu et al., 2022; Matsuzaka and Yashiro, 2022; Yao et al., 2023).
In the context of ACL injury repair, the processes of angiogenesis and fibroblast proliferation are often impeded by a relative dearth of stem cells. The introduction of MSCs may serve to bolster these processes effectively and artificially, thereby augmenting the repair of damaged tissue. Importantly, MSCs contribute not only to the healing processes but also to the restoration of ligamentous integrity through their interactions with the osseous interface (Zou et al., 2023).
This line of inquiry presents a compelling array of novel therapeutic strategies for the management of ACL injuries, offering a promising avenue for the advancement of clinical treatment protocols. The harnessing of MSCs and their exosomes represents a paradigm shift in regenerative medicine, with the potential to markedly enhance the clinical outcomes for patients afflicted with ACL injuries (Figure 3).
FIGURE 3
5.2.1.1 MSCs animal modelsIn the domain of animal studies focused on ACL injury, both MSCs and hematopoietic stem cells have demonstrated notable therapeutic potential. These cellular agents secrete a cadre of pivotal growth factors that exert positive influences on the reparative processes associated with ACL injury (Zhu et al., 2023a; Rhatomy et al., 2023). Illustratively, in a series of rat studies, whole bone marrow cells (BMCs), which were enriched with MSCs and hematopoietic stem cells, were intra-articularly injected into the joint cavity. This intervention led to a significant elevation in the levels of TGF-β1 within the knee joint fluids, thereby fostering an environment conducive to ACL healing (Park et al., 2021).
Building upon these findings, Sun et al. (2016) conducted research wherein rabbit MSCs were subjected to mechanical stimulation via radial strains at a frequency of 0.1 Hz. This mechanical stimulation was found to enhance both the proliferation and collagen production of the MSCs. In a complementary study, porcine MSCs were isolated from retro-patellar fat pads, denoted as adipose-derived stem cells (ADSCs), and from peripheral blood mononuclear cells (PBMCs). These cells were subsequently co-cultured with porcine ACL fibroblasts. The ADSCs were observed to stimulate both the proliferation and collagen production in ACL fibroblasts, while the PBMCs facilitated the migration of ligament fibroblasts. Under conditions of co-culture with ADSCs and ACL fibroblasts, there was a marked increase in collagen gene expression (Proffen et al., 2013) (Table 1).
TABLE 1
| Animal models | Cell type | Effects | References |
|---|---|---|---|
| Rat | MSCs and BMCs | Joint cavity MSC injections with elevated local TGF-β1 levels to promote ACL healing | Park et al. (2021), |
| TDSCs | TDSCs promote cell proliferation and ACL healing | Salingcarnboriboon et al. (2003) | |
| Rabbit | MSCs | MSCs promote cell proliferation and collagen production | Sun et al. (2016) |
| Pig | MSCs | MSCs and ACL fibroblast co-culture promote cell proliferation, migration, and collagen production | Proffen et al. (2013) |
| Human | MSCs | Significant improvements in damaged ACL integrity | |
| BMCs | Significant improvements in injured ACL integrity, decreased pain visual analog scale scores, and increased lower extremity functional scale scores | Moraes et al. (2013) | |
| CD34+SCs | CD34+SCs express VEGF, promote ligament healing and regeneration, angiogenesis, and improves biomechanical strength in injured ACLs | Matsumoto et al. (2012), Mifune et al. (2013), | |
| ADSCs | ADSCs differentiate into ligament cells with low HLA effects | Qin et al. (2023) | |
| TDSCs | Higher proliferation rates and in vitro osteogenic differentiation capacity than MSCs | , Kim et al. (2022) |
Different stem cell therapies used to biologically treat anterior cruciate ligament (ACL) injuries.
Abbreviations: MSCs, mesenchymal stem cells; TGFβ1, transforming growth factor β1; ACL, anterior cruciate ligament; BMCs, bone marrow cells; TDSCs, tendon and ligament-derived stem and progenitor cells; CD34+SCs, CD34+expressing stem cells; ADSCs, adipose-derived stem cells; HLA, human leukocyte antigen.
Collectively, these studies underscore the significant biological roles that MSCs and their associated cell types play in the repair of ACL injuries. Furthermore, they offer a burgeoning foundation for the development of innovative therapeutic strategies aimed at enhancing the clinical outcomes for patients suffering from ACL injuries. The insights gleaned from these preclinical investigations pave the way for future research endeavors and potential clinical applications, marking an exciting frontier in the field of orthopedic regenerative medicine.
5.2.1.2 MSCs in human ACL repairIn the quest to delineate the clinical efficacy of MSCs in the treatment of human ACL injuries, researchers have employed in situ methodologies to harvest stem cells from the damaged ACL stumps of affected patients. Post isolation, these cells undergo a meticulous characterization process, during which they are identified as MSCs based on a constellation of criteria including their adherence properties, distinctive morphological characteristics, specific surface marker expression, and their capacity for multilineage differentiation (Yin et al., 2023; Knapik et al., 2021). These observations collectively imply that the isolated stem cells may serve as viable candidates for autologous cell sources in the regeneration of the ACL.
In a pivotal study conducted by , patients presenting with ACL tear injuries were administered percutaneous injections of ACL-derived MSCs. The therapeutic outcomes were subsequently assessed using magnetic resonance imaging (MRI), a non-invasive diagnostic tool employed to quantify pixel density as an objective metric of ACL integrity. The study demonstrated significant enhancements in ACL integrity following MSC treatment, thereby positing this treatment modality as a promising non-surgical alternative for ACL injury management. These findings contribute to the burgeoning body of evidence suggesting that MSC-based therapies may offer a less invasive and equally effective approach to ACL repair, potentially transforming the standard of care for patients with ACL injuries (Table 1).
5.2.2 BMCs
BMC injections represent an effective biotherapeutic strategy for the treatment of partial ACL injuries. This approach circumvents the laborious process of systematically collecting and culturing MSCs, thereby enhancing its clinical feasibility. Furthermore, cells differentiated from hematopoietic stem cells secrete a spectrum of key growth factors and cytokines that actively contribute to the ACL healing process. In rat models, BMC injections have been associated with elevated levels of TGF-β1, suggesting a mechanism by which BMCs may promote ACL healing through the secretion of growth factors (). Consequently, BMC injections are posited as a straightforward and efficient therapeutic modality, offering novel possibilities for the management of partial ACL injuries.
Despite their therapeutic potential, BMCs necessitate further investigation to address several challenges before achieving widespread clinical application. Firstly, ACL injuries encountered in clinical practice may differ significantly from those in controlled laboratory rat models. The BMC injection method appears more applicable to partial ACL injuries, with complete ACL tears potentially requiring surgical reconstruction, albeit potentially augmented by BMC therapy. Secondly, the optimal concentrations and dosages of BMCs for human administration remain undefined. In a study by Moraes et al. (2013), precise BMC injections into injured patient ACLs, guided by fluoroscopy, demonstrated promise for treating Grade 1, 2, and possibly Grade 3 ACL lacerations (in the absence of traction). Magnetic resonance imaging (MRI) studies corroborated these findings, with improvements in ACL integrity and a reduction in patient pain visual analog scale scores, alongside an increase in lower extremity functional scale scores (Table 1). These results provide significant clinical evidence supporting the use of BMCs in the management of ACL injuries.
5.2.3 ADSCs
Adipose-derived stem cells (ADSCs) have garnered significant attention in regenerative medicine due to their unique biological properties and numerous practical benefits. One of the most notable advantages of ADSCs is their ability to be easily and safely isolated from a patient’s adipose tissue through minimally invasive procedures, such as liposuction. This accessibility makes ADSCs a viable and appealing cell source for a diverse patient population, regardless of age or health condition (Song et al., 2023; ).
ADSCs are highly versatile, with the ability to differentiate into various tissue types, including adipose, muscle, cartilage, and fibroblasts, making them ideal for treating a wide range of conditions, from degenerative diseases to traumatic injuries. Additionally, compared to BMCs, ADSCs express lower levels of human leukocyte antigen I (HLA-I), which significantly reduces the risk of immune rejection in allogeneic therapies (Qin et al., 2023).
Their enhanced immunomodulatory capacity and low immunogenicity further position ADSCs as an ideal choice for clinical applications that involve immune-related treatments, such as managing autoimmune disorders, graft-versus-host disease (GVHD), and improving organ transplantation outcomes.
In conclusion, the ease of isolation, multipotency, low immunogenicity, and robust immunosuppressive properties of ADSCs make them an especially attractive option for advancing regenerative medicine, particularly in therapies that require careful immune system management.
5.2.4 CD34+ stem cells (CD34+ SCs)
Matsumoto et al. made groundbreaking advancements in treating patients undergoing arthroscopic primary ACL reconstruction by identifying CD34+ stem cells (SCs) within damaged ACL tissues. These cells demonstrated the ability to differentiate into various cell types and migrate to ACL fracture sites, significantly contributing to the healing process. Building on this discovery, the team developed an innovative tissue-engineered contractile cell sheet technique, wrapping grafts with CD34+ SCs during ACL reconstructive surgery. This approach restored proprioception, accelerated graft maturation, and enhanced biomechanical strength while promoting the healing of the osteotendinous junction and graft ligament (Matsumoto et al., 2012; Mifune et al., 2013).
A key finding was that CD34+ SCs expressed vascular endothelial growth factor (VEGF), which stimulated angiogenesis, crucial for improving the biomechanical integrity of the repaired ACL. This pioneering method not only advanced surgical practice but also offered a new strategy in ACL injury treatment by integrating regenerative medicine and stem cell technology (). The implications of these findings are profound, paving the way for improved outcomes in ACL reconstruction. The use of CD34+ SCs in grafts enhances structural repair and supports a more comprehensive healing process, potentially reducing recovery time and improving long-term knee function. Matsumoto et al.’s research represents a significant leap in ACL treatment, laying the groundwork for future applications of regenerative approaches in orthopedic surgery.
5.2.5 Tendon and ligament-derived stem and progenitor cells (TDSCs)
In 2003, researchers made a major breakthrough by isolating pluripotent stem cells from mouse tendons, which were similar to mesenchymal stem cells (MSCs) and capable of differentiating into adipocytes, osteoblasts, and chondrocytes (Salingcarnboriboon et al., 2003). This discovery paved the way for further research that identified similar stem cells within the human anterior cruciate ligament (ACL). These ACL-derived stem cells demonstrated superior proliferation rates and osteogenic differentiation capacities compared to traditional MSCs (; Kim et al., 2022) (Table 1).
The identification of these ACL-specific stem cells has significant implications for regenerative medicine. Their ability to rapidly proliferate and differentiate offers new possibilities for developing advanced therapies for ACL injuries, potentially improving healing and outcomes for patients. This research has also expanded our understanding of the regenerative potential within tendons and ligaments, opening new avenues for tissue engineering and the development of innovative treatments for ligament repair.
In summary, the discovery of stem cells within tendons and the human ACL marks a pivotal advancement in the field, offering promising new strategies for treating ACL injuries and enhancing the prospects of regenerative medicine and tissue engineering.
5.2.6 Stem cell therapy limitations
While stem cell therapy has shown remarkable biological safety profiles, potential carcinogenicity and cancer resistance risks persist (Lu et al., 2021). Autologous isolated stem cells have little risk of immune rejection or inflammatory reactions, which are significant advantages. However, stem cells from other donors carry higher risks of immune rejection. Additionally, long-term stem cell therapy side effects remain unclear and include the possibility of attacking normal cells in recipients, thus causing bleeding and infection issues. Another critical area is how to ensure that stem cells are delivered to the right location at the right concentration to achieve effective cell proliferation and tissue regeneration while avoiding unwanted scar tissue formation (Sinkler et al., 2023; Krawetz et al., 2023). Stem cell therapy costs are also very high, which limits its popularity, especially in resource-limited settings. Therefore, while stem cell therapy shows great therapeutic potential in many aspects, it faces considerable challenges and limitations in terms of clinical applications, and more research and clinical trials are required to overcome these problems.
5.3 Growth factor therapy
In the early stages of ACL injury healing, multiple growth factors play crucial roles in the ligament repair process. These factors are vital signaling molecules that regulate tissue repair and regeneration, making them key players in initiating and guiding the healing response.
Growth factor therapy has become a popular approach for treating ACL injuries, leveraging the natural reparative properties of these molecules to enhance the body’s healing mechanisms. Research shows that growth factors promote cell proliferation, which is essential for replenishing damaged cells and supporting tissue repair. They also facilitate angiogenesis, ensuring an adequate blood supply to the injured ligament, which is crucial for the survival and function of regenerating tissue (Sha et al., 2022).
Moreover, growth factors play a significant role in remodeling the extracellular matrix (ECM), which provides structural support to the ligament. By promoting collagen synthesis and proper ECM organization, growth factors help restore the ligament’s strength and flexibility, making it more resilient to future injuries. Additionally, they enhance cell adhesion, ensuring the structural cohesion of the healing ligament.
These findings underscore the potential of growth factor therapy as a powerful tool in ACL injury treatment. As research advances, more effective therapeutic strategies are likely to emerge, improving recovery outcomes for patients and advancing regenerative medicine in orthopedics (Figure 4).
FIGURE 4
5.3.1 Epidermal growth factor (EGF)
Upon binding to the epidermal growth factor receptor (EGFR), epidermal growth factor (EGF) triggers the receptor’s tyrosine kinase activity, thereby initiating a cascade of kinases within the mitogen-activated protein kinase (MAPK) pathway. This includes the sequential activation of RAF, MEK, and ERK. The phosphorylated ERK translocates to the nucleus, where it phosphorylates a variety of transcription factors, thereby promoting the expression of genes associated with cell proliferation. The activation of EGFR also stimulates the phosphatidylinositol-3 kinase (PI3K) pathway, leading to the activation of AKT. The signaling pathway plays a pivotal role in cell proliferation and the progression of the cell cycle (Yuan et al., 2022). In rabbit ACL studies, the EGF not only significantly increased ACL fibroblast proliferation, but also enhanced protein synthesis which helped prevent mechanical property decline in damaged ACLs. This was possibly because EGF applications may have affected collagen cross-linking properties; however, further studies are required to gain a deeper understanding of collagenase activity and collagen network cross-linking characteristics in ACLs (; Zhu et al., 2023b). In McKean et al., human ACL fibroblasts were cultured by dissecting ACLs from adult male cadavers (6–24 h after death). It was observed that EGF had significant effects on human ACL-derived fibroblast adhesion and proliferation (McKean et al., 2004). However, direct injections of natural growth factors into damaged sites in patients may require continuous injections due to their rapid actions and short duration times. Other studies have reported that immobilized cytokines can act on high molecular weight substrate surfaces without depleting cytokines. For example, photo-immobilized EGF was relatively and rapidly induced and sustained human ACL fibroblast proliferation via an artificial stimulation system (Woo et al., 2007) (Table 2). These findings provide new insights and approaches for EGF use in ACL injury therapy, especially when maintaining long-lasting EGF effects. Such approaches may lead to more effective therapeutic strategies when biologically treating ACL injuries.
TABLE 2
| Signaling molecules | Animal models | Effects | References |
|---|---|---|---|
| EGF | Rabbit | Stimulates fibroblast proliferation, collagen and non-collagen synthesis and improves mechanical properties | , Zhu et al. (2023a) |
| Human | Stimulates fibroblast adhesion in ACL | McKean et al. (2004) | |
| EGF treated by photoimmobilization | Human | Rapid and sustained proliferation of human ACL fibroblasts induced by an artificial near-side stimulation system | Woo et al. (2007) |
| bFGF | Rat | Enhances cell proliferation, wound re-epithelialization, collagen deposition, and contraction, without any noticeable toxicity and inflammation | Zhang et al. (2018), Savitri et al. (2024) |
| bFGF | Rabbit | Stimulates fibroblast proliferation in ACL | Scherping et al. (1997), |
| bFGF | Human | Stimulates DNA synthesis | Yoshida and Fujii, (1999) |
| PDGF | Rat | Increases the secretion of VEGF to promote angiogenesis | Petersen et al. (2003) |
| PDGF-BB | Rabbit | Enhances the migratory ability of ACL cells | Petersen et al. (2003) |
| PDGF-BB | Rabbit | Stimulates fibroblast proliferation | Scherping et al. (1997) |
| MGF-E peptide | Human | Stimulates fibroblast proliferation | Sha et al. (2022) |
| MGF-E peptide | Human | Protects fibroblasts from hypoxia-induced apoptosis; promotes fibroblast proliferation; promotes angiogenesis | Sha et al. (2019) |
| GDF-5 | Rabbit | Stimulates fibroblast proliferation | |
| GDF-7 | Rabbit | Promotes fibroblast proliferation and increases collagen 1 expression | |
| GDF-8 | Rat | Inhibits osteogenic differentiation and the proliferation of chondrocytes | |
| Anti-GDF8 antibodies | Rat | Prevents musculoskeletal degeneration following joint injury | |
| CTGF | Rabbit | Promotes healing in injured ligamentous tissue | Zhang et al. (2017), Sun et al. (2017) |
| TGF-β | Human | Stimulates DNA synthesis but does not increase collagen synthesis | Yoshida and Fujii, (1999) |
| TGF-β | Human | Promotes extracellular matrix synthesis, affect cell differentiation, and activates Smad cell signaling pathway | Morita et al. (2021) |
| TGF-β | Sheep | Promotes early ACL injury healing in sheep | Spindler et al. (1996) |
| TGF-β | Rabbit | Stimulates collagen and non-collagen synthesis and improves mechanical properties | Sakai et al. (2002) |
Growth factor types and their effects.
Abbreviations: EGF, epidermal growth factor; ACL, anterior cruciate ligament; bFGF, basic fibroblast growth factor; PDGFBB, platelet-derived growth factor-BB; MGF-E, mechano growth factor E peptide; GDF, growth differentiation factor; CTGF, connective tissue growth factor; TGF-β, Transforming growth factor-β.
5.3.2 Basic fibroblast growth factor (bFGF)
Basic fibroblast growth factor (bFGF) initiates a signaling cascade by binding to fibroblast growth factor receptors (FGFR), thereby activating the receptor’s tyrosine kinase activity. This activation leads to the sequential engagement of kinases within MAPK pathway, notably MEK and ERK. Once activated, ERK enters the cell nucleus, phosphorylating a plethora of transcription factors, which in turn, augments the expression of genes vital for cell proliferation. Furthermore, bFGF, through its interaction with FGFR, can initiate the PI3K pathway, culminating in the activation of AKT. This signaling network is integral in modulating cellular processes such as survival and proliferation (McKean et al., 2004). bFGF significantly promoted rabbit ACL fibroblast proliferation (Scherping et al., 1997; ). Also, Yoshida and Fujii (1999) observed that bFGF stimulated DNA synthesis in human ligament cells, but no significant collagen expression changes were reported (Table 2). Further studies also showed that the 17 kDa bFGF peptide form was a major promoter of cell proliferation and was expressed in wound healing and fracture repair applications. However, under normal physiological conditions, bFGF may rapidly lose its biological activity if not stabilized. To improve its efficiency, some bFGF studies have integrated the molecule into hydrogels that release drugs in a sustained manner. This approach not only improved bFGF stability, but also enhanced its therapeutic effectiveness. Research has found that integrating bFGF into hydrogels, the bioinspired hydrogels containing bFGF can significantly enhance cell proliferation, wound re-epithelialization, collagen deposition, and contraction, without any noticeable toxicity and inflammation. However, the specific methods and effects of using them to treat ACL injuries require further exploration (Zhang et al., 2018; Savitri et al., 2024) (Table 2). Nevertheless, these findings emphasize the importance of bFGF in the treatment of ACL injuries and highlight the need for further research to improve its stability and effectiveness. Therefore, bFGF has the potential to become a key factor improving outcomes in treating ACL injuries.
5.3.3 Platelet-derived growth factor (PDGF)
Platelet-derived growth factor (PDGF) is a key mitogen in serum, exerting a significant activating effect on cells of mesenchymal origin. PDGF plays an important role in the treatment of ACL injuries, with its main therapeutic pathways including the promotion of cell proliferation and migration, and the activation of various signaling pathways involved in the remodeling of the extracellular matrix and tissue repair processes. PDGF exists in three different heterodimer forms, including AA, BB, and AB heterodimers, which exert biological effects by binding to specific receptors (Meyer-Ingold and Eichner, 1995; Zhang et al., 2023). Upon binding to its receptor PDGFR, the receptor dimer undergoes autophosphorylation, activating its tyrosine kinase activity and signaling pathways including PI3K/AKT and MAPK/ERK. These pathways promote the expression and activity of cell cycle-related proteins, such as cyclin-dependent kinases (CDKs) and cyclins, driving cells from the G1 phase into the S phase for DNA replication. PDGF is crucial for cell survival, proliferation, differentiation, and migration (Zou et al., 2022; ). Current research primarily focuses on PDGF-BB for promoting healing of ACL injuries, as the ACL does not show a significant proliferative response to PDGF-AA or PDGF-AB (Spindler et al., 1996; Scherping et al., 1997). Research by Scherping et al. indicates that PDGF-BB significantly affects the proliferation of rabbit ACL fibroblasts, suggesting an important application of PDGF in facilitating ligament healing. PDGF not only directly promotes cell proliferation but may also indirectly promote tissue repair and regeneration by affecting the synthesis and degradation of the extracellular matrix, angiogenesis, and cell migration (Scherping et al., 1997). Studies have found that after a 12-h incubation in a 1% FBS medium, 1 ng/mL of PDGF-BB significantly enhances the migratory ability of ACL cells, which may aid in the healing process of ACL injuries (Kobayashi et al., 2000). Research using rat achilles tendon fibroblasts has shown that PDGF significantly increases the secretion of VEGF by tendon cells under hypoxic conditions, demonstrating a synergistic effect that is crucial for angiogenesis and early tissue repair during ACL remodeling (Petersen et al., 2003). Given PDGF’s multiple roles in promoting cell proliferation, migration, and angiogenesis, it holds broad application prospects as a potential biotherapeutic target in the treatment of ACL injuries (). In summary, PDGF demonstrates potential in ACL injury treatment through its promotion of proliferation, migration, and angiogenesis in ACL fibroblasts, as well as its activation of signaling pathways. Future research will continue to explore the application of PDGF in tissue engineering and bio-scaffold design to achieve more effective ACL injury treatment and recovery (Table 2).
5.3.4 Force growth factor E peptide
Research by Sha et al. (2019) demonstrated that myogenic growth factor (MGF) E peptide could be used for human ACL repair and regeneration. ACL fibroblasts undergo apoptosis in severely hypoxic microenvironments. The MGF E peptide effectively protects ACL fibroblasts from hypoxia-induced apoptosis by regulating caspase 3/7/9 mRNA and related apoptotic protein expression levels while promoting cell proliferation. MGF also recruits vasculopoietic cells via the stromal cell-derived factor 1 alpha/CXCR4 axis to promote angiogenesis-generating cells and stimulate VEGFα expression, thereby promoting angiogenesis after ACL damage. It was reported that MGF promoted damaged ACL fibroblast proliferation by targeting Rac1-PAK1/2 and RhoA-ROCK1 signaling pathways (Sha et al., 2022) (Table 2). These findings highlight multiple MGF roles in treating ACL injury, including fibroblast protection, promoting cell proliferation and angiogenesis, and activating repair-related signaling pathways. Thus, MGF E peptides may provide new and promising biotherapeutic possibilities for treating ACL injuries.
5.3.5 Growth differentiation factors (GDFs)
Growth and differentiation factors (GDFs) have been identified as key signaling molecules in the embryonic development of tendons. In conjunction with TGF-β, BMPs, and FGFs, GDFs are instrumental in the embryonic genesis of tendon cells. The majority of joint tissues derive from GDF5-positive mesenchymal cells, potentially contributing to the formation of the ACL. GDFs are conjectured to possess a proteogenic role in tendon development, possibly triggering cytoskeletal reorganization or the Smad signaling cascade (Wang et al., 2021). GDF-5 and GDF-7 have demonstrated the ability to stimulate the proliferation of rabbit ACL fibroblasts. Significantly, GDF-5 has been shown to markedly enhance the expression of COL1 in ACL fibroblasts () (Table 2). This discovery implies that GDF-5 and GDF-7 are of considerable importance in the facilitation of ACL healing and regeneration. Specifically, GDF-5, by boosting COL1 expression, can aid in the restoration of structure and function in the damaged ACL. GDF8, also recognized as myostatin, is implicated in the etiology of musculoskeletal degeneration subsequent to ACL injury. GDF8 functions as an inhibitor of muscle mass and initiates Smad2/3 signaling, influencing transcriptional activity. Beyond promoting muscle atrophy, it also curbs osteogenic differentiation and the proliferation of chondrocytes (). Research has illustrated that the inhibition of GDF8 in murine models can lead to the recovery of muscle mass and functionality, as well as a decrease in the intra-articular expression of MMPs. GDF8 emerges as an early modifiable target post-ACL injury, with the administration of anti-GDF8 antibodies presenting a promising therapeutic approach against post-joint injury musculoskeletal degeneration (). Consequently, these GDFs may act as prospective biotherapeutic agents, potentially enhancing treatment strategies for ACL injuries.
5.3.6 Connective tissue growth factor (CTGF)
Connective tissue growth factor (CTGF), a member of the TGF-β superfamily, acts in concert with TGF-β to activate both Smad-dependent and Smad-independent signaling pathways. CTGF has key roles in damaged rabbit ACL healing processes and exerts its effects by upregulating COL1 and COL2 expression. This finding has provided more CTGF possibilities in treating injured tissues and promoting wound healing (Zhang et al., 2017; Sun et al., 2017) (Table 2). CTGF promotes collagen expression, which is a major fibrous component of the extracellular matrix in connective tissues, and is essential for maintaining ACL structural integrity and function. Therefore, CTGF, as a promising biotherapeutic, may be used for ACL injury treatment and recovery. These findings highlight new research directions for the biotherapeutic treatment of ACL injury and regenerative medicine in general.
5.3.7 Transforming growth factor-beta (TGF-β)
Transforming growth factor-beta (TGF-β) is a pleiotropic cytokine that plays a crucial role in cell growth, differentiation, apoptosis, tissue repair, and immune modulation. TGF-β promotes the synthesis of extracellular matrix proteins, such as collagen and fibronectin, which are major components of the cellular microenvironment. During wound healing and tissue repair, TGF-β is instrumental in facilitating cell proliferation, migration, and differentiation, as well as the synthesis of the extracellular matrix. By binding to its receptors, TGF-β activates a cascade of signaling pathways, including both Smad-dependent and Smad-independent routes (Wang et al., 2021).
In sheep ACLs, TGF-β was reported to potentially promote initial healing processes in damaged ligaments (Spindler et al., 1996). In rabbit ACL studies, TGF-β stimulated fibroblast proliferation and increased collagen and non-collagen synthesis in cells. Additionally, TGF-β prevented decreases in the mechanical properties of autologous tendons by significantly inhibiting increased water content in tendons, inhibiting cross distribution and elevated cross-sectional areas, and preventing decreases in tensile strength (Sakai et al., 2002). Yoshida and Fujii (1999) reported that TGF-β and bFGF stimulated DNA synthesis but did not collagen synthesis in human ligament cells (Table 2). These findings suggested that TGF-β may have important roles in both initial healing and long-term repair processes in ACL injury. In particular, its promotion of fibroblast functions is essential for maintaining and restoring ACL structural integrity and function. In the study by Morita et al. (2021), TGF-β was found to induce the expression of fibrosis-associated genes in tendon cells, such as Aggrecan (ACAN). TGF-β1 plays a pivotal role in tendon healing by promoting extracellular matrix synthesis, influencing cell differentiation, activating the Smad cell signaling pathway, and inducing a fibrotic phenotype. Therefore, TGF-β is a promising biotherapeutic in treating ACL injuries.
5.3.8 Combinations of different types and doses of growth factors
Growth factors, as a class of polypeptides capable of regulating cell proliferation, differentiation, and matrix synthesis, play a crucial role in ligament tissue repair. Although direct injection of growth factors can provide immediate biological activity, their application is limited by several constraints. Firstly, the half-life of growth factors is typically short, which means frequent administration is required to achieve therapeutic effects. Secondly, direct injection may lead to non-specific distribution of growth factors in the body, increasing the risk of side effects. Additionally, the direct use of growth factors may elicit an immune response, affecting their efficacy and safety. To address these issues, gene therapy offers a promising alternative strategy. By utilizing gene therapy vectors, such as recombinant adeno-associated virus (rAAV) vectors, the genes encoding specific growth factors can be directly delivered into target cells, achieving localized and sustained overexpression of multiple growth factors. This approach not only extends the active time of growth factors in the body but also reduces systemic side effects and enhances therapeutic outcomes.
Different growth factors affect various cellular processes, such as cell proliferation, differentiation, migration, and matrix synthesis. Their combined use can simultaneously activate multiple biological pathways. Some growth factors may exhibit synergistic effects when used in combination, resulting in an overall effect greater than the sum of their individual effects. In a study by Chen et al., researchers infected BMSCs with adenoviral vectors carrying BMP2 and bFGF (AdBMP2 and AdbFGF), and then implanted these cells at the tendon-bone interface. They found that the combined therapy, through the activation of the Smad pathway, promoted fibrotic-related biological processes more effectively than monotherapy in facilitating tendon-bone healing and osteogenic differentiation after ACL injury (). The overexpression of FGF-2 and TGF-β in hMSCs using rAAV vectors to promote ACL repair showed that the overexpression of these factors could enhance cell proliferation, increase DNA content, and promote the deposition of proteoglycans and collagen, contributing to improved quality and function of the repaired tissue (Stehle et al., 2024; ). The use of gene therapy vectors allows for precise control of the expression of combined growth factors, including their expression levels and duration, providing more flexibility for clinical treatment. Through gene-editing techniques, researchers can further optimize the gene sequences of growth factors to enhance their biological activity or improve their pharmacokinetic properties. This emerging technology of gene therapy combined with multiple growth factors requires further exploration of the optimal vector systems, gene-editing strategies, and administration routes in future research to achieve the best clinical outcomes of growth factor therapy.
5.3.9 Growth factor therapy limitations
Although growth factors have demonstrated multiple potential effects in treating ACL injuries in terms of promoting cell proliferation, angiogenesis, and reducing apoptosis, other considerations must be accounted for when using these therapeutic approaches. As biologically active molecules, growth factors typically have short half-lives, which lead to critical questions regarding the duration of validity, optimal time points for treatment, and frequency of use as a therapy. Answering these vital questions will ensure that their therapeutic effects are maximized. For example, growth factor application time points may affect action efficiency in healing processes, while frequency of use must ensure therapeutic efficacy while avoiding possible side effects. While growth factor therapy provides promising treatment strategies for ACL injury, their clinical application requires more research and optimization.
5.4 Gene therapy
5.4.1 Gene transfer vectors
Gene therapy, as a cutting-edge treatment, can sustainably and effectively promote ACL repair by transfecting therapeutic gene sequences which target ACL. Treatments may be conducted in two ways: by directly injecting vectors expressing therapeutic genes in vivo, or by genetically modifying cells or grafts in vitro and then reimplanting them into recipients (). Gene therapy vectors are divided into two categories: non-viral and viral vectors. The latter category includes adenovirus, herpes simplex virus (HSV), retrovirus, lentivirus, and recombinant adeno-associated virus (rAAV) vectors. With their own unique advantages and limitations, choosing appropriate vectors is critical to ensure efficacious and safe gene therapy. Gene therapy for treating ACL injuries provides an innovative approach that promotes repair and regeneration by directly modifying genes in damaged tissues or cells. With continuous developments and improvements in this field, gene therapy has great potential for treating ACL injuries.
Non-viral vectors are relatively safe choices due to their non-replication and non-immunogenic characteristics. However, as they express genes during cell division (Zu and Gao, 2021; ), gene transfer efficiencies are usually low, which is a major application limitation. In contrast, adenovirus and HSV vectors have higher transfer efficiency rates; they activate host immune responses and directly modify cells in division or quiescent phases (; ; Watanabe et al., 2021). However, immune responses may pose safety concerns. Retroviral vectors integrate into host cell genomes, thus enabling long-term transgene expression. However, they only modify dividing cells, thereby limiting their application (). RAAV vectors are considered safer alternatives, and efficiently modify dividing and quiescent cells over longer periods (Shirley et al., 2020; Verdera et al., 2020). When selecting gene therapy vectors, safety, efficiency, and applicability factors must be comprehensively considered to ensure treatment effectiveness and patient safety. With further research and technological advances, more effective and safer gene therapy vectors will be developed.
5.4.2 Therapeutic factors
5.4.2.1 Growth factorsSteinert et al. (2008) reported that after collagen hydrogel insertion into severed ACL ends, cells migrated from damaged ligaments into the hydrogel and began to repair tissue. This process was enhanced by transferring insulin-like growth factor-1 (IGF-1) cDNA into fibroblasts using adenoviral vectors to repair ACLs. In their in vitro studies, demonstrated that by encoding cDNAs for BMPs 12 and 13 and after transduction through adenoviral vectors, they promoted collagen proliferation and secretion by fibroblasts. Thus, ACL fibroblast activity was enhanced and contributed to damaged ACL repair. Researchers (Wei et al., 2008; ; ) constructed adenoviral vectors expressing TGF-β1 and VEGF165 genes. Co-expressed genes induced relatively rapid and sustained ACL fibroblast proliferation, increased COL1 and COL3 gene expression, and also fibronectin mRNA expression in rabbits, which exerted stronger and better effects on the migration and matrix synthesis of ACL fibroblasts. Madry et al. (2013) overexpressed FGF-2 using direct gene transfer mediated by rAAV vectors, which promoted human ACL injury healing. FGF-2 is a potent stimulator of fibroblast proliferation and type I/III collagen production. These studies showed that ACL repair and regeneration were effectively promoted by combining biomaterials and gene therapy techniques to treat ACL injuries (Table 3).
TABLE 3
| Vectors | Cell targets | Genes | References |
|---|---|---|---|
| Adenovirus | Fibroblast | IGF-1 | Steinert et al. (2008) |
| Adenovirus | Fibroblast | BMPs 12 and 13 | |
| Adenovirus | Fibroblast | TGF-β1 and VEGF165 | Wei et al. (2008) |
| Adenovirus | MSCs | SCX | |
| Adenovirus | MSCs | SCX, MKX | Otabe et al. (2015) |
| rAAV | Fibroblast | FGF-2 | Madry et al. (2013) |
| Lentiviral vectors | MSCs | SCX | |
| Nonviral vectors | Perichondrial cells | TGF-β | |
| Nonviral vectors | Tendon cells | BMP-7 |
Applications of gene therapy for ACL repair.
Abbreviations: rAAV, recombinant adeno-associated virus; MSCs, Mesenchymal stem cells; IGF-1, insulin-like growth factor-1; BMP, bone morphogenetic proteins; TGF-β, transforming growth factor-β; VEGF, vascular endothelial growth factor; SCX, scleraxis; MKX, mohawk; FGF, fibroblast growth factor.
5.4.2.2 Transcription factorsTranscription factors have shown great promise and unique advantages in repairing ACL injuries (Liu et al., 2014). In particular, scleraxis (Scx), Mohawk (Mkx), and early growth response factor (Egr1) have demonstrated key roles in ACL development, maturation, homeostatic maintenance, and repair (; ). SCX is mainly responsible for regulating cellular differentiation and matrix synthesis, whereas MKX affects ACL differentiation by regulating mechanical property components. Egr1 is expressed during ACL development and has important roles in ligament formation (; Liu et al., 2014; Otabe et al., 2015; ). These findings emphasized the importance of transcription factors in ACL injury repair, suggesting they are key molecules in promoting recovery in damaged ligaments. By gaining a deeper understanding of their specific roles and regulatory mechanisms, new transcription factor-based therapeutic strategies may be developed to effectively promote ACL injury repair and regeneration (Table 3).
5.4.2.3 Anti-inflammatory agentsIn early ACL healing stages, the anti-inflammatory IL-1 receptor antagonist (IL-1Ra) promoted ACL healing by stimulating M2-type macrophages and altering granulation tissue composition, which created a local, low inflammatory response environment (). Soluble tumor necrosis factor-α (TNF-α) receptors also repaired damaged ligaments, inhibited local inflammatory responses, and prevented complications such as osteoarthritis, which may occur after ACL injury (Lawrence et al., 2011). Additionally, the regulatory cytokine IL-10 acted as a positive antagonist of TNF-α in local knee joint environments after ACL injury, thus helping to prevent osteoarthritis after ACL injury (). These findings highlighted the critical role of anti-inflammatory factors in treating ACL injuries, especially when controlling inflammatory responses and promoting healing processes. Such anti-inflammatory factors may significantly improve recovery processes after ACL injury by effectively modulating local inflammatory responses in knee joints, thereby reducing complication risks. By exploiting these factors, researchers can better understand complex biological responses following ACL injury, thereby improving therapeutic outcomes and accelerating recovery. Such advances are not only important for treating ACL injuries, but provide possible treatments for other ligament and soft tissue injuries.
5.4.2.4 Matrix componentsACL contains collagen fibers, tenomodulin, core proteoglycans, fiber regulatory proteins, and disaccharide chain proteoglycans, which help maintain natural ACL structure and functional integrity. Therefore, repairing injured ACLs by transfecting vectors expressing matrix component genes may be a worthwhile therapeutic approach to naturally replicate original biological and mechanical properties in tissues (Page et al., 1992; ; Lewis et al., 2010; ; ).
5.4.3 Gene therapy limitations
Although gene therapy is a promising approach, inherent issues persist that require consideration. Firstly, due to differences in transfection methods, transfected gene expression may decrease or be lost over time. This means that gene transfection strategies must be continuously optimized and adjusted to achieve long-lasting and effective therapeutic effects. Secondly, gene therapy technologies face challenges with respect to biosafety. During treatment processes, there may be a risk of gene mutation, which can lead to unexpected biological effects or adverse reactions. Therefore, it is crucial to ensure method safety, which requires strict monitoring and the management of possible gene mutations during treatments. Finally, identifying ideal vectors is an important research area. Such vectors should have high efficiency, stability, and safety traits in ensuring gene therapy effectiveness and patient safety. These issues must be explored and improved through continuous research and trials. Therefore, gene therapy has great potential, but several technical and safety challenges must be overcome. Through future research and innovation, gene therapy will have important roles in many diverse medical fields.
5.5 Self-assembled short peptide (SAP) therapy
With rapid developments in biotherapeutic, regenerative medicine, and tissue engineering fields, SAPs have attracted much attention as emerging nanomaterials in tissue engineering. SAPs are mainly composed of amino acids, which mimic extracellular matrix properties (Luo and Zhang, 2012), and have major potential in tissue engineering and regenerative medicine fields. As biomimetic materials, SAPs provide environments similar to the natural extracellular matrix in supporting cell attachment, growth, and differentiation, traits critical in tissue repair and regeneration. Additionally, due to nanoscale and controlled biocompatibility properties, SAPs offer vast possibilities in designing and developing novel tissue engineering materials. By comprehensively examining SAP properties, their use in healing and functional recovery of injured tissues is promising.
SAP as a biological tissue engineering technology concept, although it emerged in 2022, but because it is still in an emerging stage, related research has not been widely carried out, resulting in the current published literature around this topic is rather sparse. In view of the initial state of this scientific research activity, it is obviously not appropriate to conduct accurate statistical analysis of SAP academic output and predict the trend of future publications, so the author has not carried out specific bibliometric work on this at the current stage.
5.5.1 SAP therapeutic advantages
As innovative tissue engineering materials, SAPs have significant advantages: good biocompatibility, no immune rejection issues, no cytotoxicity, and they form three-dimensional scaffold structures similar to the extracellular matrix. These properties make SAPs highly promising materials in the biomedical field, especially in tissue engineering and regenerative medicine. Studies have reported that one of the potential mechanical reasons for self-healing failure after ACL injury is the premature loss of trabecular temporary scaffolds (Tovar et al., 2012). SAPs can provide mechanical support for neoplastic cells via scaffold-like structures, which may become novel repair strategies for ACL injuries. Animal studies have shown that SAPs promote ACL injury repair in rabbits to some extent. SAPs have been demonstrated to effectively stimulate not only the functional activity and proliferative capacity of ACL fibroblasts but also the expression of both COL1 and collagen type III, thereby indicating their multifaceted role in modulating ACL tissue homeostasis. Addition, SAPs may be used as three-dimensional culture substrates for ACL fibroblasts, which adhere to and control growth factor release, thus promoting ACL injury repair. Therefore, SAPs provide new possibilities for treating ACL injuries, and are expected to improve repair and recovery processes after injury. With further research on associated properties and applications, SAPs have an exciting prospect for treating ACL injuries.
5.5.2 SAP therapy limitations
Using SAPs to repair damaged ACLs allows for minimal invasive manipulation and promising clinical applications. SAPs provide new and potentially non-reconstructive treatment modalities for ACL injury repair. However, more clarification is required regarding specific SAP molecular mechanisms in ACL repair. Understanding these processes is crucial for optimizing SAP applications, along with improving therapeutic efficacy and ensuring treatment safety. Overall, SAPs demonstrate innovative and potential non-surgical treatment avenues for ACL injuries. With future research, SAPs may provide more diverse therapeutic options for patients with ACL injuries.
5.6 Platelet-rich plasma (PRP) therapy
PRP preparations are generated by centrifuging the patient’s blood and extracting fractions rich in active platelets. These fractions are then be injected into damaged ACL joint fluid. Platelets generate many growth factors, including FGF, TGF-β, IGF, PDGF, and VEGF. PRP preparations may be directly injected into damaged areas or combined with other cells/proteins to generate gel scaffolds before implantation. The latter approach is more effective in promoting ligament fibroblast proliferation and collagen production, and is also more stable in grafts. As a result, PRP therapy significantly enhances tissue healing and angiogenesis (Moraes et al., 2013; ). Also, using the patient’s own blood, PRP provides an effective biotherapeutic strategy for treating ACL injuries, and shows great potential in improving healing efficiency and optimizing recovery processes. Thus, PRP therapy may become more clinically significant in treating ACL injuries.
5.7 BMAC
Bone marrow aspirate concentrate (BMAC) is a component rich in bone marrow mononuclear cells, isolated from the bone marrow through centrifugation, containing stem cells ready for use without the need for ex vivo expansion. BMAC can be harvested from the patient’s iliac crest during surgery or collected from the proximal region of the femur, and its widespread availability makes it ideal for clinical settings. In addition to mesenchymal stem cells, a successful BMAC harvest also contains hematopoietic stem cells, platelets rich in growth factors, BMPs, and other progenitor cells (Hogan et al., 2021). BMAC is believed to enhance the treatment of tendon injuries, knee osteoarthritis, and intervertebral disc degeneration, as well as allograft tendon regeneration and tendon-bone tunnel interface healing. The stem cells and growth factors contained in BMAC can promote the proliferation and differentiation of tendon cells, accelerating the healing process of tendon injuries (). A retrospective, single-center study showed that BMAC-enhanced open repair of sports-related Achilles tendon ruptures led to 92% of patients resuming sports without re-rupture (Stein et al., 2015). Study results indicate that the combination of BMAC and PRP demonstrates enhanced clinical outcomes, graft maturation, and tendon-bone interface healing compared to traditional ACL reconstruction surgery with PRP alone or without other biological enhancements (Lin et al., 2024). MSCs contained in BMAC can create a microenvironment that promotes tissue regeneration, stimulates angiogenesis, and reduces the formation of scar tissue. MSCs can also differentiate into various cell lines, including bone, cartilage, and ligament tissues, and recruit cells to facilitate the healing process (). BMAC therapy is an emerging biological repair method for ACL injury that has emerged in recent years. Although BMAC has shown positive results in some preliminary studies, there is still a lack of large-scale, high-quality clinical trials to support its long-term efficacy and safety. Currently, the application of BMAC lacks uniform treatment standards, including optimal dosage, injection frequency, and duration of treatment. The effectiveness of BMAC may be influenced by patient-specific factors, such as age, health status, and type of injury, which means that BMAC may not be suitable for all patients. Since BMAC is extracted from the patient’s own bone marrow, there may be significant variations in BMAC components between different patients, which could affect the consistency of treatment outcomes. Although BMAC has shown promise in some clinical applications, these limitations need to be addressed, and more research is required to enhance the evidence base for its scientific foundation and clinical effectiveness (Hogan et al., 2021).
5.8 Extracorporeal shock wave therapy
Extracorporeal shock wave therapy (ESWT) is an advanced non-invasive medical technique that utilizes high-energy shock waves to promote tissue repair and pain alleviation. Originating from urological lithotripsy, ESWT has been successfully extended to various medical fields, including the musculoskeletal system. During the treatment, the mechanical pressure generated by the propagation of shock waves within the tissue activates cellular activity, accelerating tissue repair. Concurrently, these waves can stimulate cellular signaling pathways, promoting the release of growth factors that further aid in tissue healing. Additionally, the temporary local vasodilation induced by ESWT increases blood flow, improving local circulation and oxygen supply, thereby delivering the nutrients required for the regeneration of damaged tissue. The analgesic effects of ESWT are partly attributed to its stimulation of pain-inhibiting pathways, particularly the release of endorphins (Takase et al., 2024). A study on the efficacy of Radial Extracorporeal Shock Wave Therapy (rESWT) in patients who underwent ACLR showed that rESWT is an effective and positive rehabilitation method during the early recovery period of ACLR, reducing patients’ pain levels and improving knee joint function (Song et al., 2024). The results of a study by Weninger et al. (2023) indicated that ESWT can significantly shorten the time to return to rotational sports and running activities, and increase the number of patients reaching pre-injury activity levels, making it a cost-effective treatment option with minimal side effects after ACL reconstruction. Although ESWT is widely used in the repair following anterior cruciate ligament injury, high-quality clinical evidence regarding its effectiveness remains limited, with many studies being small-scale and lacking long-term follow-up. Determining the optimal number of treatment sessions and duration of treatment remains a challenge, as overtreatment may not offer additional benefits and could potentially increase the risk of side effects (Rahim et al., 2022). To achieve broader application in medical practice, these limitations need to be addressed, and further research is required to enhance the scientific foundation and evidence base for its clinical effectiveness.
5.9 Electrical stimulation therapy
Electrical stimulation therapy, as an innovative medical approach, has demonstrated unique advantages in the treatment of musculoskeletal disorders, particularly ligament injuries. This method is not only cost-effective and safe but also highly convenient to use. As a minimally invasive or non-invasive treatment modality, it aligns well with the treatment principles advocated in the field of orthopedic sports medicine today. In the treatment of ACL injuries, electrical stimulation therapy, especially neuromuscular electrical stimulation (NMES), has proven its significant value in restoring motor function. NMES, by stimulating muscle contractions, not only promotes the healing of damaged muscles but also plays an active role in muscle rehabilitation after ACL reconstruction. This therapy can significantly improve muscle strength, increase range of motion, reduce edema, slow down muscle atrophy, accelerate tissue healing, and effectively alleviate pain, even having a positive impact on muscle enzyme activity (; Ilfeld et al., 2021).
In a randomized controlled trial examining the use of NMES after ACL injury and reconstruction, NMES significantly reduced muscle fiber atrophy, particularly affecting the fast myosin heavy chain (MHC II) fibers. At the same time, NMES also maintained the contractile ability of slow myosin heavy chain (MHC I) fibers, increased the maximum contraction speed, and maintained power output, despite having a minimal impact on MHC II fibers (Toth et al., 2020). Furthermore, NMES has shown its utility in alleviating pain, knee joint swelling in patients after ACL reconstruction, and reducing the incidence of deep vein thrombosis (DVT), becoming a simple and effective interventional treatment method (Xiong et al., 2022). After ACL reconstruction, effective analgesia is not only crucial for pain control but also helps to reduce the use of opioid medications and promotes early recovery. Given the considerable number of opioid prescriptions issued by orthopedic physicians, the potential of NMES to reduce the consumption of these drugs is particularly prominent (Hurley et al., 2023).
However, we must also recognize that the subjectivity of pain perception means that the effectiveness of electrical stimulation treatment largely depends on the patient’s self-report, which can be influenced by multiple psychological and social factors. Although electrical stimulation treatment has been widely used in pain management for ACL injuries, the exact mechanisms of its action are not fully understood, which to some extent limits the optimization and personalized adjustment of treatment. Therefore, to gain a deeper understanding of the potential of NMES and to apply it more broadly in the treatment of ACL injuries, there is an urgent need for more high-quality research to provide a solid scientific basis and guidance.
5.10 Cross bracing protocol
The prevailing view holds that once the ACL is ruptured, its capacity for self-healing is limited. However, anatomical studies have shown that the ACL has a rich blood supply, and histological studies have described that the ACL undergoes typical healing phases after injury, albeit at a slower rate and with reduced healing capacity compared to the medial collateral ligament. Cross bracing protocol (CBP), a non-surgical treatment method for ACL ruptures. Its primary goal is to attempt to promote the healing of the ACL. The specific methods include:
1. In the acute phase after ACL rupture, immobilize the knee joint in a brace at 90° flexion for 4 weeks.
2. After 4 weeks, gradually increase the range of motion of the knee joint, with adjustments made weekly.
3. Remove the brace at 12 weeks.
4. Combine with rehabilitation exercises supervised by a physiotherapist, which include target-oriented lower extremity neuromuscular control, muscle strengthening, and power training, as well as functional training aimed at helping patients resume sports and leisure activities.
A key feature of the CBP is the initial use of a brace to immobilize the knee joint at 90° flexion, based on anatomical studies that found the shortest distance between the origin and insertion points of the ACL at this angle, which may help reduce the gap between the torn ligament stumps, promoting tissue bridging and healing. The CBP also includes standardized, target-oriented, movement-based rehabilitation exercises under the guidance of a physiotherapist, as well as continued rehabilitation exercises during and after the use of the brace. Some studies have shown that after treating acute ACL ruptures with the CBP, 90% of patients had evidence of ACL healing on MRI at 3 months, and greater ACL healing on the 3-month MRI was associated with better outcomes. However, there is a scarcity of research on promoting the healing of ACL injuries with the CBP method, and longer-term follow-ups and clinical trials are needed to guide clinical practice ().